Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease.
<h4>Background</h4>Essential information regarding efficacy and safety of vitamin K-antagonists (VKA) treatment for atrial fibrillation (AF) in non-dialysis dependent chronic kidney disease (CKD) is still lacking in current literature. The aim of our study was to compare the risks of str...
Guardado en:
Autores principales: | Judith Kooiman, Nienke van Rein, Bas Spaans, Koen A J van Beers, Jonna R Bank, Wilke R van de Peppel, Antonio Iglesias del Sol, Suzanne C Cannegieter, Ton J Rabelink, Gregory Y H Lip, Frederikus A Klok, Menno V Huisman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ea0d39f8c4cc497d8666ea7f4ae219e3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Gilda Denise Zielinski, et al.
Publicado: (2020) -
Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Eleonora Camilleri, et al.
Publicado: (2021) -
Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
por: Caroline Sindet-Pedersen, et al.
Publicado: (2017) -
Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Xinxing Gao, et al.
Publicado: (2021) -
Good practices for dialysis education, treatment, and eHealth: A scoping review.
por: Anita van Eck van der Sluijs, et al.
Publicado: (2021)